Acerus Pharma enters licensing deal for Brazil

24 November 2017

Canada’s Acerus Pharmaceuticals (TSX: ASP) has signed an agreement granting exclusive rights to market Natesto in Brazil to Apsen Farmacêutica, a leading family-owned Brazil-based pharmaceutical company with over 40 products and 1,100 employees in that country.

Acerus, which changed its name from Trimel Pharmaceuticals in September 2015, saw its shares rocket 27.5% to C$0.26 yesterday following the announcement.

Natesto is a testosterone nasal gel available in a “no-touch” dispenser with a metered dose pump for reduced transference risk. It is approved and available in Canada and the USA for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK